CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A

被引:34
作者
Rosato, A
Zambon, A
Milan, G
Ciminale, V
DAgostino, DM
Macino, B
Zanovello, P
Collavo, D
机构
[1] UNIV PADUA,DEPT ONCOL & SURG SCI,DIV IMMUNOL,I-35128 PADUA,ITALY
[2] UNIV PADUA,DEPT ONCOL & SURG SCI,ONCOL SECT,I-35128 PADUA,ITALY
关键词
D O I
10.1089/hum.1997.8.12-1451
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A DNA immunization approach was used to induce an immune response against the tumor-specific antigen P815A in DBA/2 mice, The PIA gene, which encodes the P815A antigen, was modified by the addition of a short sequence coding for a tag epitope recognized by the monoclonal antibody AU1, and cloned into the eukaryotic expression vector pBKCMV, resulting in plasmid pBKCMV-P1A. L1210 cells stably transfected with pBKCMV-P1A expressed P1A mRNA and were lysed by the syngeneic P815A-specific cytotoxic clone CTL-P1:5, thus confirming that the tag-modified P1A protein underwent correct processing and presentation. A single intramuscular injection of 100 mu g of pBKCMV-P1A induced the expression of P1A mRNA for at least 4 months, Eighty percent of DBA/2 mice injected three times with 100 mu g of pBKCMV-P1A generated cytotoxic T lymphocytes (CTL) that lysed P815 tumor cells, whereas mock-inoculated animals failed to show any cytotoxicity, Moreover, experiments designed to evaluate the protection of pBKCMV-P1A-immunized mice against a lethal challenge with P815 tumor cells showed that 6 of 10 immunized mice rejected the tumor, and 2 mice showed prolonged survival compared to control animals.
引用
收藏
页码:1451 / 1458
页数:8
相关论文
共 43 条
[1]   IDENTIFICATION AND CHARACTERIZATION OF THE TUMOR-SPECIFIC P1A GENE-PRODUCT [J].
AMARCOSTESEC, A ;
GODELAINE, D ;
VANDENEYNDE, B ;
BEAUFAY, H .
BIOLOGY OF THE CELL, 1994, 81 (03) :195-203
[2]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[3]   INDIVIDUAL-DIFFERENCES IN THE ORIENTATION OF THE CYTOLYTIC T-CELL RESPONSE AGAINST MOUSE-TUMOR P815 [J].
BRICHARD, VG ;
WARNIER, G ;
VANPEL, A ;
MORLIGHEM, G ;
LUCAS, S ;
BOON, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) :664-671
[4]  
Bright RK, 1996, CANCER RES, V56, P1126
[5]  
Conry RM, 1996, GENE THER, V3, P67
[6]  
CONRY RM, 1995, GENE THER, V2, P59
[7]   Gene vaccination with naked plasmid DNA: Mechanism of CTL priming [J].
Corr, M ;
Lee, DJ ;
Carson, DA ;
Tighe, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) :1555-1560
[8]   PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS [J].
DONNELLY, JJ ;
FRIEDMAN, A ;
MARTINEZ, D ;
MONTGOMERY, DL ;
SHIVER, JW ;
MOTZEL, SL ;
ULMER, JB ;
LIU, MA .
NATURE MEDICINE, 1995, 1 (06) :583-587
[9]   DNA immunization [J].
Hassett, DE ;
Whitton, JL .
TRENDS IN MICROBIOLOGY, 1996, 4 (08) :307-312
[10]   Immunogenicity and protective efficacy of a tuberculosis DNA vaccine [J].
Huygen, K ;
Content, J ;
Denis, O ;
Montgomery, DL ;
Yawman, AM ;
Deck, RR ;
DeWitt, CM ;
Orme, IM ;
Baldwin, S ;
DSouza, C ;
Drowart, A ;
Lozes, E ;
Vandenbussche, P ;
VanVooren, JP ;
Liu, MA ;
Ulmer, JB .
NATURE MEDICINE, 1996, 2 (08) :893-898